ADC Therapeutics reported a quarterly loss of $0.04 per share versus the Zacks consensus loss of $0.32, beating estimates by $0.28. The loss narrowed from $0.29 per share a year ago (an improvement of $0.25), indicating year-over-year progress. The beat is modest and likely supportive for the stock but has limited broader market implications.
ADC Therapeutics reported a quarterly loss of $0.04 per share versus the Zacks consensus loss of $0.32, beating estimates by $0.28. The loss narrowed from $0.29 per share a year ago (an improvement of $0.25), indicating year-over-year progress. The beat is modest and likely supportive for the stock but has limited broader market implications.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
